NEK2 and lymphoma: To determine whether this synergistic effect of JH295 and rapamycin was specific to PEL or extended to nonviral lymphomas, we performed the same experiment using a KSHV- and Epstein–Barr virus (EBV)-negative diffuse large B-cell lymphoma (DLBCL) cell line (DB) and two mantle cell lymphoma cell lines (JeKo and Rec-1) that also exhibited upregulated NEK2 expression (6).